Israël - Engels - Ministry of Health

megapharm ltd - trabectedin - powder for concentrate for solution for injection - trabectedin 1 mg/vial - trabectedin - trabectedin - yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Israël - Engels - Ministry of Health

abic marketing ltd, israel - oxaliplatin - concentrate for solution for infusion - oxaliplatin 5 mg/ml - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccnguidelines, version 2.2014).

Israël - Engels - Ministry of Health

medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Europese Unie - Engels - EMA (European Medicines Agency)

virbac s.a. - purified p45 felv-envelope antigen - inactivated viral vaccines, feline leukaemia virus, immunologicals for felidae, - cats - active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - feline leukaemia - unknown - feline leukaemia vaccine active 0.0 - active constituent

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline leukaemia virus - inactivated - unknown - feline leukaemia virus - inactivated vaccine-viral active 0.0 - active constituent

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline leukaemia virus - inactivated - unknown - feline leukaemia virus - inactivated vaccine-viral active 0.0 - active constituent

Australië - Engels - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - cyanocobalamin, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. pernicious anaemia as a result of in situ b12 deficiency.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - mecobalamin, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - cobalamin deficiency may exist that is unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of vitamin b12 may be insufficient in pernicious anaemia, malabsorption disorders, gastrectomy and gastrointestinal pathologies. specific indications may include: 1. pernicious anaemia as a result of in situ b12 deficiency. in pernicious anaemia co-methylcobalamin is disproportionately reduced in relation to other cobalamins. 2. as an adjunct to the treatment of peripheral neuropathies and diabetic polyneuropathy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - cyanocobalamin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - cobalamin deficiency may exist that is unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of vitamin b12 may be insufficient in pernicious anaemia, malabsorption disorders, gastrectomy and gastrointestinal pathologies. specific indications may include: 1. pernicious anaemia as a result of in situ b12 deficiency.